Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 245-642-4 | CAS number: 23410-40-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
An extended one generation reproductive toxicity study needs only to be conducted if the available repeated dose toxicity study indicate adverse effects on reproductive organs or tissues or reveal other concerns in relation with reproductive toxicity. In the available 90 -day repeated dose toxicity study with the registration substance in rats no indictation of adverse effects on reproductive organs or tissuers reaveal concerns regarding toxicity to reproductive organs.
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
Oral: Developmental Toxicity Test (OECD 414), rat: NOAEL (maternal) ≥ 400 mg/kg bw/day; NOAEL (embryotoxicity/teratogenicity) ≥ 400 mg/kg bw/day
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 30 Aug 2019 to 30 Jan 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- June 2018
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Age at study initiation: 11 - 12 weeks old
- Weight at study initiation: between 200 and 250 g
- Fasting period before study: not reported
- Housing: individually housed in solid-bottom cages containing appropriate bedding equipped with an automatic watering valve.
- Diet: PMI Nutrition International, LLC Certified Rodent LabDiet® 5002 (meal) was provided ad libitum
- Water: Municipal tap water after treatment by reverse osmosis was freely available to each animal via an automatic watering system.
- Acclimation period: prior to the initiation of dosing.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 26
- Humidity (%): 30 - 70
- Air changes (per hr): 10 or more
- Photoperiod (hrs dark / hrs light): 12-hr light/12-hr dark - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The dosing formulations were prepared every 4 days and an adequate amount of each formulation was dispensed into daily aliquots, which were stored at room temperature, protected from light, under nitrogen, until use.
VEHICLE
- Lot/batch no. (if required): 2IC0148 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analyzed dosing formulations contained 107% to 114% of the test substance which was within the protocol-specified range of target concentrations for suspensions (85% to 115%) and were homogeneous.
- Details on mating procedure:
- - Impregnation procedure: purchased timed pregnant
- Duration of treatment / exposure:
- single daily oral gavage dose during Gestation Days 6 through 20
- Frequency of treatment:
- single daily dose
- Duration of test:
- from Gestation Days 6 through 20
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 400 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 25 dams/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Doses were based on a dose range-finding study, in which 5 males and 5 females (non-pregnant) Sprague Dawley rats per dose group via oral gavage for up to 14 consecutive days at dosage levels of 0, 90, 180, 300, and 500 mg/kg bw/day. At 500 mg/kg/day, the test substance caused moribundity, leading to unscheduled euthanasia, and thus exceeds a maximum tolerated dose. Therefore, the dose levels selected for this study were 0, 50, 150, and 400 mg/kg bw/day.
- Rationale for animal assignment: Animals were assigned to groups by a stratified randomization scheme designed to achieve similar group mean body weights. Animals in poor health or at extremes of body weight range were not assigned to groups. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily, once in the morning and once in the afternoon.
- Cage side observations included, but were not limited to: labored breathing, fur staining, thinning fur, abnormal gait, decreased activity, and increased salivation.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily, beginning on the day of receipt and lasting through euthanasia
BODY WEIGHT: Yes
- Time schedule for examinations: individually on Gestation Days 0 (by supplier) and 5 - 21 (daily)
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 21
- Organs examined: liver and kidneys
OTHER: Blood samples for thyroid hormone analyses were collected (prior to noon in order to avoid diurnal fluctuations in thyroid hormone levels) via a jugular vein into tubes without anticoagulant - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Placentae were also examined - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: half per litter - Statistics:
- All statistical tests were conducted at the 5% significance level. All pairwise comparisons were conducted using two sided tests and are reported at the 1% and 5% levels.
Body weight; body weight gain; food consumption; gravid uterine weight and corrected maternal body weights; litter means; organ weights; and anogenital distance: Levene's test was used to assess the homogeneity of group variances. The groups were compared using an overall one-way ANOVA F-test if Levene's test was not significant or the Kruskal-Wallis test if it was significant. If the overall F-test or Kruskal-Wallis test was found to be significant, then pairwise comparisons were conducted using Dunnett's or Dunn's test, respectively.
Ovarian and uterine content; litter % of fetuses with external/visceral/skeletal abnormalities: The groups were compared using an overall Kruskal-Wallis test. If the overall Kruskal-Wallis test was found to be significant, then the above pairwise comparison was conducted using Dunn's test.
Parental indices and mortality; macroscopic findings; microscopic findings: A Fisher’s Exact Test was used to conduct pairwise group comparisons of interest.
Thyroid hormone analysis: The groups were compared using an overall one-way ANOVA F-test. If the overall F-test is found to be significant, then pairwise comparisons will be conducted using Dunnett's test. - Indices:
- Postimplantation Loss/Litter = (No. Dead Fetuses, Resorptions (Early or Late) per Group) / (No. Gravid Females per Group) X 100
Summation Per Group (%) = (Sum of Postimplantation Loss per Litter) / (No. Litters per Group) X 100
Postimplantation Loss/Litter (%) = (No. Dead Fetuses, Resorptions (Early or Late) per Group) / (No. Implantation Sites per Litter) X 100 - Historical control data:
- Charles River Ashland has historical data on the background incidence of fetal malformations and developmental variations in the Crl:CD(SD) rat.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Labored breathing and/or abnormal breathing sounds were noted for 17 of 25 females in the 400 mg/kg bw/day group at the daily examinations and/or 1 - 2 hours following dose administration generally throughout the study (Gestation Days 8 - 21). Abnormal breathing sounds were also noted for 8 of 25 females in the 150 mg/kg bw/day group during Gestation Days 7 - 19, albeit to a lesser extent than noted in the 400 mg/kg bw/day group.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female in the 150 mg/kg bw/day group was found dead on gestation day 18. No clinical observations or noteworthy changes in body weight were noted for this female prior to death, and no macroscopic findings were observed at necropsy. In the absence of unscheduled deaths in the high-dose group, this mortality was not considered test substance-related.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Mean maternal body weights, body weight gains, corrected body weights, corrected body weight gains, and gravid uterine weights in the 50, 150, and 400 mg/kg bw/day groups were unaffected by test substance administration. Differences from the control group were slight and not statistically significant, with the following exceptions. A statistically significantly higher mean body weight gain during Gestation Days 6 - 7 and lower mean body weight gain during Gestation Days 20 - 21 were noted in the 400 mg/kg bw/day group compared to the control group. Because these body weight changes failed to produce a noteworthy effect on the overall body weight gain and absolute mean body weights in this group, they were considered transient and unrelated to test substance administration.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Mean maternal food consumption, evaluated as g/animal/day and g/kg/day, in the 50, 150, and 400 mg/kg bw/day groups was unaffected by test substance administration. Differences from the control group were slight and not statistically significant.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related effects on mean TSH, T3, or T4 concentrations were noted at any dose level. Mean TSH concentration in the 400 mg/kg bw/day group females was 21.8% lower than the control group. This decrease was not considered test substance-related because the difference from the control group was not statistically significant, and there were no effects on thyroid gland weight or histopathology in the thyroid at this dose level.
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- not specified
- Details on maternal toxic effects:
- Intrauterine growth and survival were unaffected by test substance administration at dose levels of 50, 150, and 400 mg/kg bw/day. Parameters evaluated included mean litter proportions of postimplantation loss, mean number of viable/live fetuses, mean fetal body weights, and fetal sex ratios. Differences from the control group were slight, not statistically significant, and/or did not occur in a dose-related manner.
Mean numbers of corpora lutea and implantation sites and the mean litter proportions of pre-implantation loss were similar across all groups. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: No adverse effects observed
- Key result
- Abnormalities:
- effects observed, non-treatment-related
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related skeletal malformations were observed in fetuses in this study. Two fetuses in the 150 mg/kg bw/day group each had an absent lumbar vertebra. This finding was not considered test substance-related because no skeletal malformations were noted in the high-dose group. No other skeletal malformations were noted in this study.
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related visceral malformations were observed in fetuses in this study. One fetus in the 50 mg/kg bw/day group had a retroesophageal right subclavian artery; however, this finding was not observed in a dose-related manner, and therefore was not considered test substance-related. No other visceral malformations were noted in this study.
- Other effects:
- no effects observed
- Description (incidence and severity):
- Mean anogenital distance (absolute and relative to cube root of body weight) was unaffected by test substance administration at all dose levels. Differences from the control group were slight and not statistically significant.
- Details on embryotoxic / teratogenic effects:
- Mean mean number of viable/live fetuses, mean fetal body weights, and fetal sex ratios were unaffected by treatment. Mean anogenital distance (absolute and relative to cube root of body weight) was unaffected by test substance administration at all dose levels. No test substance-related skeletal or visceral malformations were observed in fetuses in this study.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 400 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed
- Key result
- Abnormalities:
- effects observed, non-treatment-related
- Key result
- Developmental effects observed:
- no
- Conclusions:
- In an oral gavage developmental study conducted in accordance to OECD 414 and to GLP, the NOAEL for N-[3-(dimethoxymethylsilyl)-2-methylpropyl]ethylenediamine for maternal toxicity and embryo/fetal development was 400 mg/kg bw/day, as no significant adverse effects were observed up to the highest dose of 400 mg/kg bw/day tested in rats.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 400 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The study was conducted according to the OECD test guideline 414, and in compliance with GLP.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
In an oral gavage study conducted in accordance to OECD 414 study guidelines and GLP standards, pregnant female rats were exposed with N-[3-(dimethoxymethylsilyl)-2-methylpropyl]ethylenediamine (CAS 23410-40-4) during gestation days 6 through 20 at dose levels of 0, 50, 150, or 400 mg/kg bw/day.
With regards to maternal toxicity, no test substance-related effects on survival were noted at any dosage level. One female in the 150 mg/kg bw/day group was found dead on gestation day 18. No clinical observations or noteworthy changes in body weight were noted for this female prior to death, and no macroscopic findings were observed at necropsy. In the absence of unscheduled deaths in the high-dose group, this mortality was not considered test substance-related. Labored breathing and/or abnormal breathing sounds were observed generally throughout the study (gestation days 7–21) in 8 out of 25 females in the 150 mg/kg bw/day group and 17 out of 25 females in the 400 mg/kg bw/day group. These observations were considered test substance-related due to the absence in control group animals, but non-adverse, as the overall health and well-being of the animals were not impacted by these clinical observations. Mean maternal body weights, body weight gains, corrected body weights, corrected body weight gains, gravid uterine weights, and food consumption in the 50, 150, and 400 mg/kg bw/day groups were unaffected by test substance administration. Thyroid hormones (T3, T4, and TSH) were unaffected by test substance administration at 50, 150, and 400 mg/kg/day. There were no test substance-related macroscopic or microscopic findings or effects on organ weights noted at any dose level.
Intrauterine growth and survival and fetal anogenital distance were not affected by test substance administration at any dose level. There were no test substance-related fetal malformations or developmental variations noted at any dose level.
In conclusion, based on the absence of adverse maternal and embryo/fetal effects in this study, the dosage level of 400 mg/kg/day was considered to be the no-observed-adverse-effect level (NOAEL) for maternal toxicity and embryo/fetal development when N-[3-(dimethoxymethylsilyl)-2-methylpropyl]ethylenediamine (CAS 23410-40-4) was administered orally by gavage to time-mated Crl:CD(SD) rats.
Justification for classification or non-classification
The available data is reliable and suitable for classification. Based on this data, classification for toxicity to reproduction according to EC/1272/2008 is not warranted.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
